Results 121 to 130 of about 807,832 (329)
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Molecular Oncology, EarlyView.We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...Marina N. Sharifi, Eric Feng, Nicholas R. Rydzewski, Amy K. Taylor, Jamie M. Sperger, Yue Shi, Kyle T. Helzer, Matthew L. Bootsma, Viridiana Carreno, Alex H. Chang, Luke A. Nunamaker, Grace C. Blitzer, Tianfu Andy Shang, Aishwarya Subramanian, Anders Bjartell, Andreas Josefsson, Pernilla Wikström, Emily Feng, Manish Kohli, Rendong Yang, Scott M. Dehm, Eric J. Small, Rahul Aggarwal, David A. Quigley, Joshua M. Lang, Shuang G. Zhao, Martin Sjöström +26 morewiley +1 more sourcePATHOLOGY [PDF]
Neuro-Oncology, 1992 J.-i. Adachi, K. Totake, M. Shirahata, K. Mishima, T. Suzuki, T. Yanagisawa, K. Fukuoka, R. Nishikawa, A. Arimappamagan, N. Manoj, A. Mahadevan, D. Bhat, H. Arvinda, B. Indiradevi, S. Somanna, B. Chandramouli, S. A. Petterson, S. K. Hermansen, R. H. Dahlrot, S. Hansen, B. W. Kristensen, F. Carvalho, S. Jalali, S. Singh, S. Croul, K. Aldape, G. Zadeh, J. Choi, S.-H. Park, S. K. Khang, Y.-L. Suh, S. P. Kim, Y. S. Lee, S. H. Kim, S. Coberly, K. Samayoa, Y. Liu, P. Kiaei, J. Hill, S. Patterson, M. Damore, S. Dahiya, R. Emnett, J. Phillips, D. Haydon, J. Leonard, A. Perry, D. Gutmann, S. Epari, S. Ahmed, M. Gurav, S. Raikar, A. Moiyadi, P. Shetty, T. Gupta, R. Jalali, J. Georges, A. Zehri, E. Carlson, N. Martirosyan, A. Elhadi, J. Nichols, L. Ighaffari, J. Eschbacher, B. Feuerstein, T. Anderson, M. Preul, K. Jensen, P. Nakaji, H. Girardi, F. Monville, S. Carpentier, M. Giry, J. Voss, R. Jenkins, B. Boisselier, V. Frayssinet, C. Poggionovo, A. Catteau, K. Mokhtari, M. Sanson, H. Peyro-Saint-Paul, C. Giannini, T. Hide, H. Nakamura, K. Makino, S. Yano, S. Anai, N. Shinojima, J.-i. Kuroda, T. Takezaki, J.-i. Kuratsu, F. Higuchi, H. Matsuda, K. Iwata, K. Ueki, P. Kim, J. Kong, L. Cooper, F. Wang, J. Gao, G. Teodoro, L. Scarpace, T. Mikkelsen, M. Schniederjan, C. Moreno, J. Saltz, D. Brat, U. Cho, Y.-K. Hong, Y. S. Lee, R. Lober, L. Lu, M. H. Gephart, P. Fisher, M. Miyazaki, H. Nishihara, T. Itoh, M. Kato, S. Fujimoto, T. Kimura, M. Tanino, S. Tanaka, N. Nguyen, G. Moes, J. L. Villano, H. Nishihara, H. Kanno, Y. Kato, S. Tanaka, T. Ohnishi, H. Harada, S. Ohue, S. Kouno, A. Inoue, D. Yamashita, S. Okamoto, M. Nitta, Y. Muragaki, T. Maruyama, T. Sawada, T. Komori, T. Saito, Y. Okada, S. B. Omay, J. M. Gunel, V. E. Clark, J. Li, E. Z. E. Omay, A. Serin, L. E. Kolb, R. M. Hebert, K. Bilguvar, K. Ozduman, M. N. Pamir, T. Kilic, J. Baehring, J. M. Piepmeier, C. W. Brennan, J. Huse, P. H. Gutin, K. Yasuno, A. Vortmeyer, M. Gunel, A. Perry, S. Pugh, C. L. Rogers, D. Brachman, W. McMillan, J. Jenrette, I. Barani, D. Shrieve, A. Sloan, M. Mehta, A. Prabowo, A. Iyer, T. Veersema, J. Anink, A. S.-v. Meeteren, W. Spliet, P. van Rijen, T. Ferrier, D. Capper, M. Thom, E. Aronica, T. Chharchhodawala, M. Sable, M. C. Sharma, C. Sarkar, V. Suri, M. Singh, V. Santosh, B. Thota, M. Srividya, K. Sravani, S. Shwetha, A. Arivazhagan, K. Thennarasu, B. Chandramouli, A. Hegde +199 moreopenaire +2 more sourcesTOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis
Molecular Oncology, EarlyView.TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.Ranakul Islam, Megan E. Roche, Zhao Lin, Diana Whitaker‐Menezes, Victor Diaz‐Barros, Eurico Serrano, Maria Paula Martinez Cantarin, Nancy J. Philp, Atrayee Basu Mallick, Ubaldo Martinez‐Outschoorn +9 morewiley +1 more sourcePlasma lipidomic and metabolomic profiles in high‐grade glioma patients before and after 72‐h presurgery water‐only fasting
Molecular Oncology, EarlyView.Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.Iris Divé, Lisa Hahnefeld, Katharina J. Wenger, Donat Kögel, Joachim Steinbach, Gerd Geisslinger, Michael W. Ronellenfitsch, Irmgard Tegeder +7 morewiley +1 more sourceTranscriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM
Molecular Oncology, EarlyView.CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.Julia Latowska‐Łysiak, Żaneta Zarębska, Marcin P. Sajek, Adriana Grabowska, Alessia Buratin, Paweł Głodowicz, Julia O. Misiorek, Konrad Kuczyński, Stefania Bortoluzzi, Marek Żywicki, Jan G. Kosiński, Agnieszka Rybak‐Wolf, Rafał Piestrzeniewicz, Anna M. Barciszewska, Katarzyna Rolle +14 morewiley +1 more source